Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Yant

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Molecular Pharmaceutics|November 2, 2023
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Jennifer Tang, Jim Zheng, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2024
Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stabilityAndrew Mulato, Eric Lansdon, Ron Aoyama, et al.
Nature|December 7, 2021
Long-acting capsid inhibitor protects macaques from repeat SHIV challengesSamuel J Vidal, Elena Bekerman, Derek Hansen, et al.
Stem Cells (Dayton, Ohio)|October 14, 2006
Sarcoma derived from cultured mesenchymal stem cellsJakub Tolar, Alma J Nauta, Mark J Osborn, et al.
Ebiomedicine|August 25, 2023
Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIVAdrienne E Swanstrom, Robert J Gorelick, Jorden L Welker, et al.
Nature Medicine|September 11, 2019
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse modelStephen R Yant, Andrew Mulato, Derek Hansen, et al.
Journal of Medicinal Chemistry|October 1, 2025
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, Winston Tse, Scott D Schroeder, et al.
Nature|July 3, 2020
Clinical targeting of HIV capsid protein with a long-acting small moleculeJohn O Link, Martin S Rhee, Winston C Tse, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Molecular Pharmaceutics|November 2, 2023
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Jennifer Tang, Jim Zheng, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2024
Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stabilityAndrew Mulato, Eric Lansdon, Ron Aoyama, et al.
Nature|December 7, 2021
Long-acting capsid inhibitor protects macaques from repeat SHIV challengesSamuel J Vidal, Elena Bekerman, Derek Hansen, et al.
Stem Cells (Dayton, Ohio)|October 14, 2006
Sarcoma derived from cultured mesenchymal stem cellsJakub Tolar, Alma J Nauta, Mark J Osborn, et al.
Ebiomedicine|August 25, 2023
Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIVAdrienne E Swanstrom, Robert J Gorelick, Jorden L Welker, et al.
Nature Medicine|September 11, 2019
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse modelStephen R Yant, Andrew Mulato, Derek Hansen, et al.
Journal of Medicinal Chemistry|October 1, 2025
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, Winston Tse, Scott D Schroeder, et al.
Nature|July 3, 2020
Clinical targeting of HIV capsid protein with a long-acting small moleculeJohn O Link, Martin S Rhee, Winston C Tse, et al.
Pageof 4